PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

Ann: Successful MPSVI Safety Review and PARA OA 008 Update, page-79

  1. 1,704 Posts.
    lightbulb Created with Sketch. 1853
    Hi Zenox

    I noticed you were not expecting any change in the cartilage degrading products such as COMP and ADAMTS-5 in the synovium at Day 56 from baseline - suggesting these could take longer.

    Can I ask, is this specifically due to the fact the readings are from the synovium? The Phase 2b results showed a material reduction in both of these markers at Day 53 in the serum samples from that trial.

    https://hotcopper.com.au/data/attachments/4711/4711231-bffb6e5821cdd1f6a68de3c16f8915e6.jpg



 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.